About this trial
Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.
Eligibility criteria
Qualifiers
Receiving germline testing related to primary cancer condition initiated by oncologist
18 years old or older.
Speak and read English
Disqualifiers
Receiving cancer genetic testing via a referral to a genetics clinic
Do not speak or read English
Under 18 years of age
Determined to have diminished, marginal and or fluctuating decisional capacity
Trial design
Treatments tested in this trial
- Genetics Adviser for Mainstream Care (GA-Mainstream)
- Mainstreaming Standard of Care